<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117433</article-id><article-id pub-id-type="publisher-id">ACM-43777</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_24493318.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  microRNA-221-3p在肝纤维化治疗中的研究进展
  Research Progress of microRNA-221-3p in the Treatment of Liver Fibrosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>毛</surname><given-names>青松</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>龚</surname><given-names>建平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市长寿区人民医院肝胆外科，重庆</addr-line></aff><aff id="aff3"><addr-line>重庆医科大学附属第二医院肝胆外科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>2986</fpage><lpage>2991</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  肝脏会对外界刺激做出反应尝试修复或取代受损细胞，从而在肝内形成的异常大量的瘢痕组织，被称为肝纤维化，是肝硬化的前期病变。小分子RNA (microRNA)是一类内源基因非编码单链小RNA分子，可通过转录后抑制调节细胞的增殖、分化、凋亡及免疫应答等重要生命过程。最新的研究发现，在慢性肝损伤过程中，阻断肝细胞中的microRNA-221-3p功能，能够加快沉积的细胞外基质的溶解，在一定程度上缓解肝纤维化的进展。该文通过整理国内外相关文献对miRNA-221-3p在肝纤维化治疗研究进展作一综述，为临床上更好的治疗肝纤维化提供充分的理论基础和思路。
   When liver cells are damaged by stimulation, the liver will respond to stress to try to repair or replace the damaged cells. As a result, an abnormally large amount of scar tissues are formed in the liver. This is called liver fibrosis, which is a major cause of liver insufficiency. Small RNA (microRNA) is a type of endogenous gene non-coding single-stranded small RNA molecule that can regulate cell proliferation, differentiation, apoptosis, immune response and other important life processes through post-transcriptional inhibition. The latest research found that in the process of chronic liver injury, blocking the function of microRNA-221-3p in liver cells is beneficial to the recovery of the liver, accelerating the dissolution of deposited extracellular matrix, and alleviating the progress of liver fibrosis to a certain extent, has important clinical significance. This article summarizes the research progress of miRNA-221-3p in the treatment of liver fibrosis by collating relevant domestic and foreign literature, and provides a sufficient theoretical basis and ideas for better clinical management of liver fibrosis.
 
</p></abstract><kwd-group><kwd>肝纤维化，microRNA，microRNA-221，研究进展, Liver Fibrosis</kwd><kwd> microRNA</kwd><kwd> microRNA-221</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肝脏会对外界刺激做出反应尝试修复或取代受损细胞，从而在肝内形成的异常大量的瘢痕组织，被称为肝纤维化，是肝硬化的前期病变。小分子RNA (microRNA)是一类内源基因非编码单链小RNA分子，可通过转录后抑制调节细胞的增殖、分化、凋亡及免疫应答等重要生命过程。最新的研究发现，在慢性肝损伤过程中，阻断肝细胞中的microRNA-221-3p功能，能够加快沉积的细胞外基质的溶解，在一定程度上缓解肝纤维化的进展。该文通过整理国内外相关文献对miRNA-221-3p在肝纤维化治疗研究进展作一综述，为临床上更好的治疗肝纤维化提供充分的理论基础和思路。</p></sec><sec id="s2"><title>关键词</title><p>肝纤维化，microRNA，microRNA-221，研究进展</p></sec><sec id="s3"><title>Research Progress of microRNA-221-3p in the Treatment of Liver Fibrosis<sup> </sup></title><p>Yong Guo<sup>1</sup>, Qingsong Mao<sup>2</sup>, Jianping Gong<sup>2*</sup></p><p><sup>1</sup>Department of Hepatobiliary Surgery, People’s Hospital of Changshou District in Chongqing, Chongqing</p><p><sup>2</sup>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/14-1572362x4_hanspub.png" /></p><p>Received: Jun. 7<sup>th</sup>, 2021; accepted: Jun. 28<sup>th</sup>, 2021; published: Jul. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/14-1572362x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>When liver cells are damaged by stimulation, the liver will respond to stress to try to repair or replace the damaged cells. As a result, an abnormally large amount of scar tissues are formed in the liver. This is called liver fibrosis, which is a major cause of liver insufficiency. Small RNA (microRNA) is a type of endogenous gene non-coding single-stranded small RNA molecule that can regulate cell proliferation, differentiation, apoptosis, immune response and other important life processes through post-transcriptional inhibition. The latest research found that in the process of chronic liver injury, blocking the function of microRNA-221-3p in liver cells is beneficial to the recovery of the liver, accelerating the dissolution of deposited extracellular matrix, and alleviating the progress of liver fibrosis to a certain extent, has important clinical significance. This article summarizes the research progress of miRNA-221-3p in the treatment of liver fibrosis by collating relevant domestic and foreign literature, and provides a sufficient theoretical basis and ideas for better clinical management of liver fibrosis.</p><p>Keywords:Liver Fibrosis, microRNA, microRNA-221, Research Progress</p><disp-formula id="hanspub.43777-formula8"><graphic xlink:href="//html.hanspub.org/file/14-1572362x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1572362x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1572362x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝纤维化被认为是肝脏对包括酒精、肝炎、毒素和免疫化合物在内的慢性肝损伤的伤口愈合反应，常见的引起肝纤维化甚至肝硬化的原因是慢性感染 [<xref ref-type="bibr" rid="hanspub.43777-ref1">1</xref>]。纤维化表现为肝星状细胞(HSCs)的活化、细胞外基质的过度积累和肝细胞功能障碍，长期反复的肝纤维化会导致肝功能衰竭。肝纤维化是一种可逆的病变过程，且其预后较好，但如发展为肝硬化则具有严重的临床后果，因此肝纤维化的治疗具有重要的临床意义和价值，发现一种新的治疗肝纤维化的方法将极大的降低肝硬化、肝癌患者的发病率，为医学界的福音。目前大部分的研究都集中在阐明肝纤维化过程中肝细胞功能的变化及相关意义，但作为肝脏主要实质细胞的肝细胞的调节功能仍有待进一步了解。最新研究表明microRNA221-3p在肝纤维化的发生发展过程中起着十分重要的作用，本文通过综合相关论著，得出了miRNA-221-3p可以作为一个治疗肝纤维化的新的靶点的重要结论。</p></sec><sec id="s6"><title>2. miRNA和miRNA-221/222的基本概述</title><p>miRNA是细胞内源性长度为125个核苷酸的单链非编码小RNA，广泛存在于真核生物中，miRNA基因通常被RNA聚合酶II转录 [<xref ref-type="bibr" rid="hanspub.43777-ref2">2</xref>]，经过加工，即5’端加帽，3’端多聚腺苷化形成初级转录产物pri-miRNA。然后在核内经过RNaseIII酶Drosha和Pasha (DGCR8)剪切，形成约60 nt的前体(premiRNA)，即未成熟的茎环结构。Pre-miRNA在GTP依赖的exportin-5蛋白帮助下转运进入细胞质，随后在细胞质中被RnaseIII Dicer剪切成为成熟miRNA，约为22 bp的双螺旋结构。之后，经过RNA双链解旋酶解螺旋，双链中1条进入并与RNA介导沉默复合体结合(RNA-induced silencing complex, RISC)。miRNA通过与靶基因3’非翻译端(3’UTR)互补配对 [<xref ref-type="bibr" rid="hanspub.43777-ref3">3</xref>]，使结合后的miRNA/RISC复合体或通过翻译抑制下调特定基因产物，或直接导致mRNA降解。通常一个miRNA可能有数百个靶基因，一个miRNA也可能含有不同miRNA的多个潜在结合位点。miRNA在包括胚胎发育、干细胞自我更新以及肿瘤的发生、发展、侵袭、转移和耐药等广泛的生理和病理过程中起作用。miR-221和miR-222 (miRNA221/222)位于同一染色体Xp11.3上，拥有共同的种子序列，两者具有高度同源性，由其中一个可以预知另一个的靶基因且发挥相同的生物学作用。Zhao [<xref ref-type="bibr" rid="hanspub.43777-ref4">4</xref>] 等研究发现，单独敲掉miR-22或miR-222和共同敲掉两者的表达在对基因的调控功能上没有明显的差异。最新的研究发现miR-221-3p是一种潜在的纤维化调节因子 [<xref ref-type="bibr" rid="hanspub.43777-ref5">5</xref>]。</p></sec><sec id="s7"><title>3. 肝纤维化病理进程中各种miRNA的差异性表达</title><p>肝纤维化是各种慢性肝病发展到肝硬化过程中的主要病理学改变 [<xref ref-type="bibr" rid="hanspub.43777-ref6">6</xref>]。为了明确肝纤维化进程中miRNA的变化，Ninomiya [<xref ref-type="bibr" rid="hanspub.43777-ref7">7</xref>] 等用基因芯片技术分析肝硬化患者血清中的miRNA表达谱，与正常组比较，miRNA-505-3p和miRNA-197-3p的表达下调。Murakami [<xref ref-type="bibr" rid="hanspub.43777-ref7">7</xref>] 等通过miRNA芯片分析了miRNA在小鼠肝纤维化模型和人类临床样本中的表达，在小鼠肝纤维化模型中，有11种miRNA与肝纤维化的病理进程相关。重要的是，4种高表达的miRNA (miRNA-199a, miRNA-199a, miR-200a和miR-200b)在人和小鼠的肝纤维化组织中具有相同的序列 [<xref ref-type="bibr" rid="hanspub.43777-ref8">8</xref>]；Roderburg [<xref ref-type="bibr" rid="hanspub.43777-ref9">9</xref>] 等用四氯化碳制备肝纤维化小鼠模型，6~8周后，miRNA-29的家族成员(miR-29a，miR-29b和miR-29c)的表达比正常肝组织显著下调。多年研究表明，大量miRNAs通过调节HSCs的活化、增殖、凋亡以及衰老等过程而参与肝纤维化的发生发展阶段 [<xref ref-type="bibr" rid="hanspub.43777-ref10">10</xref>]。不同的miRNAs亚型参与肝纤维化的程度和方式有所不同。</p></sec><sec id="s8"><title>4. miRNA221-3p对肝纤维化进展及治疗中的调控作用</title><sec id="s8_1"><title>4.1. miRNA221-3p在肝纤维化中表达升高</title><p>HSC (肝星状细胞)的激活是肝纤维化过程中的一个重要事件 [<xref ref-type="bibr" rid="hanspub.43777-ref10">10</xref>]。HSC位于Dissel间隙内，富含大量VitA脂滴，一旦受到外界因素催化，那么肝脏内部的HSC细胞就会改变静息状态出现活化趋势，HSC逐步变为促使肝纤维化的有关细胞，在活化中表现出细胞外基质并形成肌成纤维，严重影响到肝功能的正常运作 [<xref ref-type="bibr" rid="hanspub.43777-ref11">11</xref>]。肝纤维化的特点是细胞外基质的积累，HSC被认为是产生ECM的主要细胞类型，HSC表型的改变在肝纤维化病理过程中起着至关重要的作用 [<xref ref-type="bibr" rid="hanspub.43777-ref12">12</xref>]。最新的研究发现，模拟转染miR-221-3p和miR-17-5p后，小鼠体内TIMP1水平显著升高。此外，miR-221-3p模拟转染也导致Col1a1、Acta2和Tgfbr1等特征性纤维化标志物mRNA水平升高。而为了进一步验证miRNA221-3p具有调节纤维化的作用，Hsin-Chieh Tsay [<xref ref-type="bibr" rid="hanspub.43777-ref13">13</xref>] 测定了在BALB/c小鼠注射CCl4 8周后诱导的肝纤维化小鼠模型中miR-221-3p水平，然后通过天狼星红染色和Col1a1、Acta2、Tgfbr1等原纤维化标志物的miRNA表达分析证实了肝纤维化，这些原纤维化标志物在纤维化小鼠肝脏中表达增加。接着通过原位杂交在肝纤维化组织中观察到miRNA-221-3p高表达，通过qPCR分析，也证实了肝纤维化组织中miRNA-221-3p水平升高。将肝纤维化肝脏的初级细胞进行灌注纯化并离心后，小鼠纤维化组织中分离的肝细胞中miRNA-221-3p的表达明显高于正常健康肝细胞。在HSC中，miRNA-221-3p也显著上升。</p></sec><sec id="s8_2"><title>4.2. MiR-221-3p可加快肝纤维化在体内的溶解</title><p>Hsin-Chieh Tsay分别向经过尾静脉高压注射CCL4后6周和8周的小鼠注射TuD-miRNA-221-3p (AAV TuD)的腺相关病毒(AAV)血清，以抑制纤维化肝脏细胞中的miRNA-221-3p。在证实了体内miRNA-221-3p抑制后，通过组织学和天狼星红染色确定纤维化。与对照组相比较，注射AAV TuD的小鼠肝脏损伤减少，天狼星红染色区域减少。与对照组相比，注射AAV TuD的小鼠血清中的天门冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)和胆红素水平均明显下降，均提示在体内抑制miRNA-221-3p可减轻肝脏损伤。肝星状细胞活化标志物在miR-221-3p抑制作用下降低，促纤维化标志物的mRNA水平，Col1a1，Acta2，Tgfbr1均显著下降。</p></sec></sec><sec id="s9"><title>5. miRNA221-3p对肝纤维化的调控机制</title><sec id="s9_1"><title>5.1. miRNA-221-3p在肝纤维化过程中对GNAI2的转录后调控</title><p>有研究显示，在慢性肝损伤期间阻断肝细胞中的miRNA-221-3p功能，能够促进肝脏的恢复和沉积的细胞外基质的更快消除，其机制是miRNA-221-3p对G蛋白α抑制活性多肽2 (GNAI2)的转录后调节，减少了碳–碳基序趋化因子配体2的分泌，减轻了肝纤维化 [<xref ref-type="bibr" rid="hanspub.43777-ref14">14</xref>]。与健康肝脏细胞相比较，纤维化肝细胞的GNAI2蛋白水平有所降低。而在注射AAV TuD的纤维化肝脏小鼠肝细胞中，GNAI2 mRNA表达和GNAI2蛋白水平均被抑制。除了GNAI2，Hsin-Chieh Tsay还检测了GNAI3的表达，它是Gi组的一员，在肝病中经常被下调。在体内抑制miR-221-3p后，肝细胞中GNAI3蛋白水平未被调节，说明在转录后水平上，只有GNAI2而非GNAI3受到miR-221-3p的调节。</p></sec><sec id="s9_2"><title>5.2. MiRNA-221-3p通过GNAI2抑制HSC活化</title><p>Hsin-Chieh Tsay发现在GNAI2过表达小鼠原始肝细胞共培养的45个肝细胞中，P75ntr、Acta2和Des的mRNA和蛋白水平均显著下调，而将共培养肝细胞与肝星状细胞中的GNAI2表达抑制后，加入miRNA-221-3p抑制剂，抗纤维化的作用明显降低 [<xref ref-type="bibr" rid="hanspub.43777-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.43777-ref16">16</xref>]。CCL2的促炎症反应已经是公认的事实，CCL2作为一种促炎性趋化因子，能诱导多种炎性细胞因子和趋化因子的表达，放大炎症反应并损伤组织细胞，因此与肝纤维化密切相关 [<xref ref-type="bibr" rid="hanspub.43777-ref17">17</xref>]。此前有报道称，在mice31中，一旦GNAI2被敲低，趋化因子CCL2就会升高，而在注射AAV TuD的肝纤维化小鼠肝细胞中，Ccl2 mRNA表达下调，将GNAI2在小鼠原始肝细胞里过表达后，CCL2分泌明显减少 [<xref ref-type="bibr" rid="hanspub.43777-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.43777-ref19">19</xref>]。同样的，在转染了miRNA221-3p抑制剂的小鼠原始肝细胞培养基中的上清液中，通过ELISA证实了CCL2水平下降。而在肝星状细胞里，过表达CCL2后，Col1a1、Acta2、p75NTR、Tgfbr1的表达都明显的升高；p75NTR、αSMA和Desmin也明显的升高。这些结果都证明了GNAI2的上调抑制了肝细胞中Ccl2 mRNA和Ccl2蛋白的表达，从而抑制了HSC的活化，改善了肝纤维化。而CCL2不仅能是肝星状细胞的有效激活因子，还能促进骨髓单核细胞的趋化 [<xref ref-type="bibr" rid="hanspub.43777-ref20">20</xref>]。流式细胞分析显示，将miRNA-221-3p抑制后，单核细胞募集的减少(CD11b和F4/80细胞数量减少)同样有助于减轻肝细胞的纤维化。</p></sec></sec><sec id="s10"><title>6. 小结</title><p>肝纤维化是肝硬化的前期表现，其患者往往无特异性临床症状，但当其发展为肝硬化时，可出现消化系统相关症状及相关并发症，如消化不良、食欲不佳、黄疸等症状，大量腹腔积液、门静脉高压、上消化道大出血等并发症，最终导致肝衰竭的发生。因此，针对肝纤维化的治疗具有重要的临床价值。目前抗纤维化治疗主要集中在预防肝星状细胞的活化、纤维化的抑制以及解决已经形成的纤维化。然而，肝细胞由多达80%的肝脏实质细胞组成，并负责介导多种不同类型的细胞之间的相互作用，如肝星状细胞、枯否式细胞和上皮细胞。临床上目前针对肝纤维化并无特异性的治疗方法，主要通过去除诱因和使用保肝药物来减缓肝纤维化进展速度，对不良生活方式和肥胖导致的肝纤维化，提倡进行管理生活方式来逆转纤维化。随着研究的进展，发现miRNA-221-3p在肝纤维化的调控机制中具有重要意义，因此将miRNA-221-3p作为一个新的靶向肝细胞治疗肝纤维化的靶点，其可行性具有非常大的研究价值。</p></sec><sec id="s11"><title>文章引用</title><p>郭 勇,毛青松,龚建平. microRNA-221-3p在肝纤维化治疗中的研究进展Research Progress of microRNA-221-3p in the Treatment of Liver Fibrosis[J]. 临床医学进展, 2021, 11(07): 2986-2991. https://doi.org/10.12677/ACM.2021.117433</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43777-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Yu, X., Zhu, C., Wang, Z., Zhao, Z., Li, Y. and Zhang, Y. (2019) Notum Attenuates HBV-Related Liver Fibrosis through Inhibiting Wnt 5a Mediated Non-Canonical Pathways. Biological Research, 52, Article No. 10.  
&lt;br&gt;https://doi.org/10.1186/s40659-019-0217-8</mixed-citation></ref><ref id="hanspub.43777-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Balmant, N.V., de Souza Reis, R., Pinto Oliveira, J.F., Ferman, S., de Oliveira Santos, M. and de Camargo, B. (2016) Cancer Incidence among Adolescents and Young Adults (15 to 29 years) in Brazil. Journal of Pediatric Hematology/Oncology, 38, 88-96. &lt;br&gt;https://doi.org/10.1097/MPH.0000000000000541</mixed-citation></ref><ref id="hanspub.43777-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Di, C., Li, W., Cai, W., Tan, X., Xu, L., et al. (2016) Erratum to: Oncomirs miRNA-221/222 and Tumor Suppressors miRNA199a/-195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis. Digestive Diseases and Sciences, 61, 3373. &lt;br&gt;https://doi.org/10.1007/s10620-016-4289-9</mixed-citation></ref><ref id="hanspub.43777-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dentelli, P., Traversa, M., Rosso, A., Togliatto, G., Olgasi, C., Marchiò, C., et al. (2014) miR-221/222 Control Luminal Breast Cancer Tumor Progression by Regulating Different Targets. Cell Cycle, 13, 1811-1826.  
&lt;br&gt;https://doi.org/10.4161/cc.28758</mixed-citation></ref><ref id="hanspub.43777-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Verjans, R., Peters, T., Javier Beaumont, F., van Leeuwen, R., van Herwaarden, T., Verhesen, W., et al. (2018) MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. Hypertension, 71, 280-288. &lt;br&gt;https://doi.org/10.1161/HYPERTENSIONAHA.117.10094</mixed-citation></ref><ref id="hanspub.43777-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Aydın, M.M. and Akçalı, K.C. (2018) Liver Fibrosis. Turkish Journal of Gastroenterology, 29, 14-21.  
&lt;br&gt;https://doi.org/10.5152/tjg.2018.17330</mixed-citation></ref><ref id="hanspub.43777-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Murakami, Y., Toyoda, H., Tanaka, M., Kuroda, M., Harada, Y., Matsuda, F., et a1. (2011) The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families. PLoS ONE, 6, e16081.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0016081</mixed-citation></ref><ref id="hanspub.43777-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., et al. (2010) Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research, 6, 45-55. &lt;br&gt;https://doi.org/10.1158/1078-0432.ccr-09-1630</mixed-citation></ref><ref id="hanspub.43777-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2010) Global and Regional Mortality from 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2095-2128. &lt;br&gt;https://doi.org/10.1016/s0140-6736(12)61728-0</mixed-citation></ref><ref id="hanspub.43777-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">尤鸿美, 王凌, 卜芳田, 孟宏武, 潘雪银, 张亚飞, 王傲, 黄成, 李俊. MicroRNAs在肝纤维化进展中的作用[J]. 中国药理学通报, 2021, 37(2): 171-175.</mixed-citation></ref><ref id="hanspub.43777-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J.C., Chen, R., Luo, X., Li, Z.-H., Luo, S.-Z. and Xu, M.-Y. (2019) MicroRNA-194 Inactivates Hepatic Stellate Cells and Alleviates Liver Fibrosis by Inhibiting AKT2. World Journal of Gastroenterology, 25, 4468-4480.  
&lt;br&gt;https://doi.org/10.3748/wjg.v25.i31.4468</mixed-citation></ref><ref id="hanspub.43777-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ju, B., Nie, Y., Yang, X., Wang, X., Li, F., Wang, M., et al. (2019) miR-193a/b-3p Relieves Hepatic Fibrosis and Restrains Proliferation and Activation of Hepatic Stellate Cells. Journal of Cellular and Molecular Medicine, 23, 3824-3832. &lt;br&gt;https://doi.org/10.1111/jcmm.14210</mixed-citation></ref><ref id="hanspub.43777-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ma, L., Liu, J., Xiao, E., Ning, H., Li, K., Shang, J., et al. (2021) MiR-15b and miR-16 Suppress TGF-β1-Induced Proliferation and Fibrogenesis by Regulating LOXL1 in Hepatic Stellate Cells. Life Sciences, 270, Article ID: 119144. 
&lt;br&gt;https://doi.org/10.1016/j.lfs.2021.119144</mixed-citation></ref><ref id="hanspub.43777-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">原琪, 王贞香, 刘雨娟, 马文娟, 安琼. 肝纤维化中星状细胞的作用机制及靶向治疗[J]. 医学食疗与健康, 2021, 19(4): 200-201.</mixed-citation></ref><ref id="hanspub.43777-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, S., Chen, X., Li, X.-F., Chen, S.-Y., Li, J.-J., Wang, A., et al. (2020) Role of Micro RNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update. Current Pharmaceutical Design, 26, 1-12.  
&lt;br&gt;https://doi.org/10.2174/1381612826666201023143542</mixed-citation></ref><ref id="hanspub.43777-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Roscigno, G., Quintavalle, C., Donnarumma, E., Puoti, I., Diaz-Lagares, A., Iaboni, M., et al. (2016) MiR-221 Promotes Stemness of Breast Cancer Cells by Targeting DNMT3b. Oncotarget, 7, 580-592.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.5979</mixed-citation></ref><ref id="hanspub.43777-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Tsay, H.C., 张笑晨, 胡玉琳. 特异性抑制肝细胞miRNA-221-3p可减轻肝纤维化[J]. 临床肝胆病杂志, 2019(5): 1094.</mixed-citation></ref><ref id="hanspub.43777-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Borst, K., Frenz, T., Spanier, J., Tegtmeyer, P.K., Chhatbar, C., Skerra, J., et al. (2017) Type I Interferon Receptor Signaling Delays Kupffer Cell Replenishment during Acute Fulminant Viral Hepatitis. Journal of Hepatology, 68, 682-690. &lt;br&gt;https://doi.org/10.1016/j.jhep.2017.11.029</mixed-citation></ref><ref id="hanspub.43777-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Maschmeyer, P., Flach, M. and Winau, F. (2011) Seven Steps to Stellate Cells. Journal of Visualized Experiments, 51, 2710.</mixed-citation></ref><ref id="hanspub.43777-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">陈健民, 谭丽秋, 蒋俊俊, 梁冰玉, 周燕. 趋化因子CCL2对大鼠学习记忆的影响及其机制[J]. 中国药理学通报, 2019, 35(7): 962-967.</mixed-citation></ref></ref-list></back></article>